← back to picks
Founded 1973 · Osong/Cheongju Reporting KRW Credit A- · Korea Ratings/NICE Valuation 2026-05-31 Damodaran FCFF · 1000-iter MC FCFF · Dark v3

A wide moat the equity can't get paid for · −64.8% margin of safety

SELL — market prices the equity as if ₩377b net debt weren't there

Intrinsic value ₩7,013/share (after a 15% Korea-governance haircut; pre-haircut ₩8,251) vs market ₩19,920. The Monte Carlo median is ₩8,731 and 95% of 1,000 draws land below today's price — the franchise is real, but ₩435b gross debt plus ₩52b of minorities consume ₩429b of the ₩521b enterprise value, leaving only ~₩92b for shareholders against a ₩222b market cap.

p5 ₩2,169 p25 ₩5,622 p50 ₩8,731 p75 ₩13,160 p95 ₩19,867 DCF ₩7,013 MARKET ₩19,920
SectorHealthcare products — hard capsules + HFF OEMCountry mixKR 61% · CN 12% · DE 9%β / MC σ2.76 levered (bottom-up) · ±₩5,311/sh (1000 runs)GovernanceYang family ~55% · 15% haircutQuality≥95% Korea capsule share · A- · ~4.8× ND/EBITDALeverageGross debt ₩435b · minorities ₩52b
Intrinsic / share
₩7,013.22
post 15% gov · pre ₩8250.84
Market / share
₩19,920.00
29 May 2026 close · KOSPI
Margin of safety
-64.8%
vs intrinsic
Enterprise value
₩520.96B
74.5% terminal
Cost of equity / debt
17.57% / 3.38%
β 2.76 · CRP 0.82%
Terminal ROIC / g
7.50% / 2.75%
spread ~-67bp (ROIC 7.50% vs WACC 8.17%)

What it sells, where it sells

Operating segments

₩722.3B FY25 revenue
Health functional food (HFF)OEM/ODM supplements, China-export-led; the growth leg but structurally lower-margin — the part diluting the capsule moat41%
Hard capsule≥95% Korea share, global top-3; regulatory switching-cost lock-in for the life of each approved molecule — the real moat32%
Raw materials / gelatinVertical integration into the capsule input (Geltech) — defensive, cyclical on input cost16%
Pharma + cosmeticsPharma fill (8%) low-cyclicality; cosmetics (2%, Korea Cosmo) the small tail10%

The moat lives in the 32% hard-capsule line (≥95% Korea share, regulatory lock-in) — but the part that is growing is the 41% HFF OEM book, structurally lower-margin and resting heavily on a single Chinese client with lumpy order cycles. That mix shift is exactly why a 9–12% historical operating-margin franchise now prints ~7%, and why the base case credits only a partial recovery to 8%.

Country mix (revenue-weighted CRP input)

🇰🇷South Korea61%
🇨🇳China12%
🇩🇪Germany9%
🇺🇸United States5%
🇮🇩Indonesia4%
🇹🇭Thailand3%
🇻🇳Vietnam3%
🇯🇵Japan3%

Korea-heavy (61%) keeps the weighted country-risk premium low at ~0.82%, but the 12% China weight is the swing variable: it is the HFF-export engine behind the bull case and the single-client concentration behind the bear case. The Vietnam (3%) line is where the mistimed, debt-funded 2023–24 capsule capacity build still sits under-absorbed.

Background — five things to know before the case

Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.

Where we diverge from the sector

Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.

Assumption
Our input
Sector median
Value impact
01Revenue growth10-year revenue CAGR vs Healthcare Products median
~4.3% CAGR5% Y1-5 (mature capsule + normalizing HFF) fading to 2.75% terminal — down-weighting the unrepeatable 2024-25 China export spike
~5.0% CAGRHealthcare Products, global cross-sector median
₩0
02Operating marginYear-5 target vs sector median EBIT margin
8.0%User bear-trim from a 9% base — a partial, not full, recovery from the 7.0% FY25 level; HFF mix dilution caps the rebound at the low end of the 8-12% band
~12%Healthcare Products sector median operating margin
−₩large
03Sales-to-capitalReinvestment efficiency vs sector median
1.1× → 1.25×Asset-heavy capsule-plant build phase rising as 2021-24 Vietnam/HFF capacity reaches utilization
~1.30×Healthcare Products industry standard
−₩small
04Terminal growthYear 10+ steady state vs KRW risk-free ceiling
2.75%Below the 3.65% KRW risk-free — modest discount reflecting Korea's low-growth demographics
~3.65%KRW risk-free ceiling — Damodaran's stable-growth cap
₩0
05Cost of capital10y WACC vs WACC implied by the suppressed regression β
8.17%Bottom-up levered β 2.76 (Healthcare Products β_u 1.1165 re-levered at D/E ~1.96) · CRP 0.82% · KRW rf 3.65% · Kₑ 17.57%
~4.29%Suppressed 5Y regression β 0.48 (3 sources) — rejected; implies an impossible β_u ≈ 0.19
−₩large
Net effect of overrides
The overrides are deliberately conservative and net negative vs a naive build. The single biggest move is rejecting the suppressed 0.48 regression β for a bottom-up 2.76, which lifts WACC from an indefensible 4.29% to 8.17% — and because terminal ROC (7.5%) then sits below WACC, every reinvested won destroys value in steady state (engine diagnostic fired). The 8% margin (user bear-trim from 9%) and the 15% governance haircut compound the caution. None of this is what makes the equity expensive, though — the ₩377b net debt does.
−₩large
Our override Sector median Override adds value Override subtracts value

The story & the five claims

The 10-year story this DCF is built on, plus the five anchor claims that translate the story into engine inputs.

The 10-year story

Suheung is a real wide-moat franchise — it makes ≥95% of Korea's hard capsules, sits in the global top-three, and its customers are locked in for the life of every approved drug by regulatory switching costs. The problem is not the business; it is the balance sheet. Gross debt of ₩435b and ₩52b of minority interests swallow ₩429b of the ₩521b enterprise value, so only about ₩92b is left for shareholders against a ₩222b market cap. The market looks at a 7.7× P/E and a 0.5× book and calls it cheap, but that cheapness is a leverage mirage — the equity is priced as if the ₩377b of net debt simply weren't there. On a conservative build — 5% revenue growth fading to a 2.75% terminal, operating margin recovering only part-way to 8% (a bear-trim from the 9% base, which leaves terminal returns just below the cost of capital), a bottom-up beta of 2.76 rejecting the implausibly suppressed 0.48 regression, and a 15% Korea-governance haircut — intrinsic value is ₩7,013 against today's ₩19,920, a −64.8% margin of safety. The Monte Carlo agrees: its median is ₩8,731 and 95% of a thousand correlated draws land below the market price. This is a SELL, a moat you cannot get paid for — the only way the equity doubles is if the balance sheet heals (deleveraging plus a capsule-margin normalization toward ~15% plus a Korea Value-up re-rating), and that is a bet on the financing, not the operations.

Two debates worth pressure-testing

Isn't a 7.7× P/E and 0.5× book obviously cheap?
Our view: No — it's a leverage mirage. Those multiples look at the thin equity sliver on top of ₩377b net debt. On enterprise value, ₩435b gross debt plus ₩52b minorities consume ₩429b of the ₩521b EV, leaving ~₩92b of equity value against a ₩222b market cap. The market is pricing the equity as if the debt weren't there; subtract it properly and intrinsic is ₩7,013 vs ₩19,920 — a −64.8% margin of safety, not a bargain.
Is rejecting the observed 0.48 β for a bottom-up 2.76 fair, or piling on pessimism?
Our view: Fair, and it actually cuts against the SELL. A 0.48 regression β (3 sources agree) implies an unlevered β of ~0.19 — economically impossible for a levered capsule maker; it reflects illiquid Korean-smallcap low KOSPI co-movement, not low business risk. The orchestrator's robustness check shows WACC is invariant at 8.17%/8.53%/8.80% across D/E 1.96/0.80/0.40 — only the 0.48 outlier gives 4.29%. A higher WACC lowers value, so the conservative β makes the SELL harder to reach, not easier; the equity is still overvalued anyway.
CLAIM 01Blended revenue compounds ~5% Y1-5, fading to 2.75% terminal.growth_high: 5.0% · terminal: 2.75% · ₩722B → ₩1,103BMature mid-single-digit capsule core blended with a normalizing-off-a-high-base HFF export book. Deliberately down-weights the unrepeatable +232%/+119% 2024-25 China spike rather than annualizing it.
CLAIM 02Operating margin recovers only part-way, to 8%.target_op_margin: 8% from Y5 (base 7.02%)A user bear-trim from the 9% narrative base. The 11.7%→5.2%→7.0% slide was cyclical-plus-mix, recoverable but capped: the part that is growing (HFF OEM) is structurally lower-margin. This is the single load-bearing claim. At 8% the terminal ROC sits below WACC.
CLAIM 03Reinvestment stays asset-heavy.S2C: 1.1× Y1-5 → 1.25× Y6-10A capsule-plant model running below the ~1.30 sector standard; the rise reflects the 2021-24 Vietnam/HFF capacity reaching utilization — the operating-leverage story behind the margin recovery, not an independent assumption.
CLAIM 04Recovery converges by Year 5.year_of_convergence: 5Suheung is a mature franchise in a cyclical turnaround, not a young-growth company. Margin reaches the 8% target by year 5; growth then decays linearly toward the 2.75% terminal rate with no further expansion.
CLAIM 05Going concern intact, but a thin (negative) steady-state spread.terminal_g: 2.75% · failure: 2% · gov haircut: 15% · stable ROC 7.5% < WACC 8.17%A- rating, ≥95% share — failure is a 2% token tail, not a distress case. The honest risk is a thin spread: ~4.8× ND/EBITDA lifts the KRW cost of capital so terminal ROC (7.5%) lands just below WACC — every reinvested won destroys value in steady state. The deep 0.5× book is partly rational.
Where we diverge from sell-side
  • We value the enterprise, then subtract the debt — sell-side anchors on the equity multiple. Sell-side 12m targets of ₩28k–42k (median ₩35k) imply ~29% upside off a 7.7× P/E. That ignores that ₩429b of the ₩521b EV is spoken for by ₩435b gross debt and ₩52b minorities. Properly netted, the equity is worth ~₩92b, not ~₩222b.
  • Operating margin held at 8%, not reverted to the ~12% sector median. The mix shift toward lower-margin HFF OEM is a permanent cap on the rebound; we credit a partial, bear-trimmed recovery, not a full mean-reversion to the historical peak.
  • β set to a bottom-up 2.76, not the suppressed 0.48 regression. The 0.48 (3 sources) implies an impossible unlevered ~0.19; using the Healthcare Products β_u 1.1165 re-levered at D/E ~1.96 lifts WACC to 8.17% rather than flattering the valuation with a 4.29% discount rate.
  • Terminal ROC faded below WACC — and we leave it there. At the 8% margin, stable ROC is 7.5% against an 8.17% WACC, so the steady state destroys value (engine diagnostic fired). We do not paper over it with an unfaded perpetual-moat assumption.
  • Governance haircut 15%, heavier than a clean public name. Yang family ~55%, unstable ~13-20% payout, one-off-flattered FY25 earnings. Above the standard-public 5%, below the abuse band of 25-30%.
Two-sided case — bear anchors
  • The equity is simply overvalued on the cash flows. Intrinsic ₩7,013 vs market ₩19,920 — a −64.8% margin of safety. The MC median is ₩8,731 and P(intrinsic < market) is 95%. The market is paying ~2.8× our intrinsic estimate for the equity.
  • Refinancing ₩435b gross debt at higher KRW rates while the single Chinese HFF client doesn't renew. This is the council's #1 failure mode. Net debt/EBITDA ~4.8x with OCF covering only ~19% of total debt leaves little cushion if the cost of borrowing rises into a soft HFF order cycle.
  • Margin fails to clear 8%. If permanent HFF mix dilution holds the operating margin at the FY25-ish 7% (or worse, back toward the 5.2% trough), the steady-state spread goes firmly negative and most of the already-thin equity value evaporates.
  • Earnings quality keeps disappointing. FY25 net income was flattered by a ~₩14-17b non-recurring associate gain; the underlying run-rate is lower than statutory EPS implies, so even the cheap-looking multiple is overstated.
  • The Korea-discount persists. ~55% family control, low unstable payout, and no Value-up catalyst means the minority-shareholder cash-flow capture stays suppressed indefinitely — the 0.5× book is not necessarily a coiled spring.

Risks to thesis (tail, not bear case)

Leverage / refinancingHigh

₩435b gross debt, net debt ~₩377b (~4.8× EBITDA), OCF only ~19% of total debt, interest cover ~1.9×. Refinancing at higher KRW rates into a soft HFF order cycle is the council's identified thesis-ender. The thin equity sliver swings violently on small EV moves.

Margin fails to recover to 8%High

The single load-bearing claim. Permanent HFF mix dilution could cap the margin at ~7% or revert toward the 5.2% trough; at 7.5% the steady-state spread over WACC is already negative and most explicit-period value erodes.

Single-client HFF concentrationMed

China HFF export growth rests heavily on one client with short, lumpy contracts and re-order cycles. One non-renewal breaks the 5% blended-growth forecast and spikes quarterly variance, as a Q3'25 export claim already showed.

Earnings qualityMed

FY2025 net income (~₩43.5b) was flattered by a ~₩14-17b non-recurring Naturalendo associate valuation gain. Statutory EPS overstates underlying earnings power, so even the cheap-looking multiple is overstated.

Korea-discount / family controlLow

Yang family ~55%, 3rd-gen succession, low unstable ~13-20% payout. A persistent overhang on minority cash-flow capture, already priced via the 15% governance haircut — a drag, not a near-term break.

Bull re-rating (upside risk)Low

Deleveraging + capsule-margin normalization toward ~15% + a Korea Value-up re-rating could double the equity — the Expansionist case. But it is a bet on the balance sheet healing, not on the operations, and none of it is in the base case.

10-year forecast

Revenue ₩722.3B → ₩1,102.7B over 10y (5% Y1-5 blended recovery, fading to 2.75% terminal). Operating margin recovers only part-way, from 7.02% base to 8.0% by Y5 — a user bear-trim from the 9% narrative base, leaving terminal returns just below the cost of capital.

Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 0 1.1T rev (KRW) 0% 10% op margin revenue FCFF op margin

Monte Carlo distribution

The Monte Carlo median is ₩8,731 and 95% of 1,000 correlated draws land below today's ₩19,920 — only the extreme p95 tail (₩19,867) even approaches the market price. The distribution prices business uncertainty, and on almost every path the equity is worth far less than what the market pays.

p5 p25 p50 p75 p95 market 19920.00 -1612.5 8731.2 26569.1 freq equity / share (KRW)

Mean ₩9677.31 ± ₩5311.36/sh, 1000 iterations (0 failed). P(intrinsic < market ₩19920.00) = 95.0%.

⚠ Active diagnostic: stable_state.override_roc (0.0750) < WACC (0.0817); every dollar reinvested in stable state destroys value
Cost of capital build
Risk-free rate 3.65%
Mature-market ERP 4.23%
Levered β 2.76
Weighted CRP 0.82%
Cost of equity 17.57%
Pre-tax cost of debt (synth Baa2/BBB) 4.50%
D / V ~66%
WACC 8.17%
Full year-by-year DCF
Year Revenue Op mgn EBIT EBIT(1−t) Reinvest FCFF PV
1 ₩758.42B 7.22% ₩54.73B ₩41.05B ₩32.83B ₩8.21B ₩7.59B
2 ₩796.35B 7.41% ₩59.03B ₩44.27B ₩34.47B ₩9.80B ₩8.37B
3 ₩836.16B 7.61% ₩63.62B ₩47.71B ₩36.20B ₩11.51B ₩9.10B
4 ₩877.97B 7.80% ₩68.52B ₩51.39B ₩38.01B ₩13.38B ₩9.77B
5 ₩921.87B 8.00% ₩73.75B ₩55.31B ₩39.91B ₩15.40B ₩10.40B
6 ₩963.81B 8.00% ₩77.11B ₩57.83B ₩33.56B ₩24.27B ₩15.16B
7 ₩1.00T 8.00% ₩80.27B ₩60.20B ₩31.61B ₩28.59B ₩16.53B
8 ₩1.04T 8.00% ₩83.20B ₩62.40B ₩29.30B ₩33.10B ₩17.72B
9 ₩1.07T 8.00% ₩85.86B ₩64.39B ₩26.62B ₩37.77B ₩18.74B
10 ₩1.10T 8.00% ₩88.22B ₩66.16B ₩23.61B ₩42.55B ₩19.58B
Methodology & flags

Damodaran FCFF DCF, 10y explicit + perpetuity, in KRW. Risk-free 3.65% (local-currency government bond). Synthetic credit Baa2/BBB. CRP 0.82% from revenue-weighted country mix × Damodaran 2026 CRPs. Terminal ROIC faded to 7.50%; 15% governance haircut applied post-DCF. Monte Carlo: 1000 iterations. Engine v1.0.0 · result: /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/suheung/output/2026-05-31-result.json

  • R&D cap: OFF · Lease cap: OFF · Failure: ON · ESO: OFF
  • Governance haircut: 15% applied post-DCF (₩8250.84 > ₩7013.22)
  • Sensitivity tornado: not run